Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer
• * Stage III or IV disease
• The following histologic epithelial cell types are allowed:
• * Serous adenocarcinoma
• * Mucinous adenocarcinoma
• * Clear cell adenocarcinoma
• * Endometrioid adenocarcinoma
• * Mixed epithelial carcinoma
• * Undifferentiated carcinoma
• * Transitional cell carcinoma
• * Malignant Brenner tumor
• * Adenocarcinoma not otherwise specified
• Must have undergone appropriate surgery for ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer within the past 6 weeks
• No borderline ovarian tumor of low malignant potential
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• GOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Hemoglobin ≥ 8.0 g/dL
• Platelet count ≥ 100,000/mm\^3
• Hepatic
• Bilirubin normal
• Meets 1 of the following criteria:
• * Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)
• * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
• * AP ≤ 5 times ULN AND AST or ALT normal
• No hepatic disease that would preclude study participation
• Renal
• Creatinine ≤ 2.0 mg/dL
• Creatinine clearance \> 50 mL/min
• No renal disease that would preclude study participation
• Cardiovascular
• LVEF ≥ lower limit of normal\*
• No poorly controlled arrhythmia
• No unstable coronary artery disease
• No myocardial infarction within the past year NOTE: \*LVEF evaluation performed only on patients requiring it
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
• No peripheral neuropathy ≥ grade 2
• No other nonmalignant systemic disease that would preclude study participation
• No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
• No medical, social, or psychosocial factor that would preclude study participation
• No psychiatric or addictive disorder that would preclude giving informed consent
• No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix or breast
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior immunotherapy for this malignancy
• Chemotherapy
• No prior chemotherapy for this malignancy
• Endocrine therapy
• No prior hormonal therapy for this malignancy
• Radiotherapy
• No prior radiotherapy for this malignancy
• Surgery
• See Disease Characteristics
• No planned interval cytoreductive surgery
• * Second-look surgery allowed
• Other
• More than 1 year since prior experimental or investigational therapy
• No concurrent therapeutic anticoagulation with warfarin